For research use only. Not for therapeutic Use.
ML-210（Cat No.:I011957）is a small-molecule inhibitor known for selectively targeting mutant p53, a protein frequently altered in cancer that drives tumor progression and resistance to therapy. By destabilizing mutant p53, ML-210 induces apoptosis in cancer cells reliant on aberrant p53 function, helping suppress tumor growth. Its specificity makes it a valuable compound in studying p53’s role in oncogenesis and exploring targeted cancer therapies. ML-210’s potential to modulate key apoptotic pathways positions it as a promising agent in precision oncology, particularly in cancers with p53 mutations.
| Catalog Number | I011957 |
| CAS Number | 1360705-96-9 |
| Synonyms | CID 49766530; CID-49766530; CID49766530; ML-210; ML 210; ML210.;[4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone |
| Molecular Formula | C22H20Cl2N4O4 |
| Purity | ≥95% |
| Target | Metabolic Enzyme/Protease |
| Solubility | Soluble in DMSO |
| Storage | Store at 2-8 °C |
| IUPAC Name | [4-[bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone |
| InChI | InChI=1S/C22H20Cl2N4O4/c1-14-20(28(30)31)19(25-32-14)22(29)27-12-10-26(11-13-27)21(15-2-6-17(23)7-3-15)16-4-8-18(24)9-5-16/h2-9,21H,10-13H2,1H3 |
| InChIKey | VIBHJPDPEVVDTB-UHFFFAOYSA-N |
| SMILES | CC1=C(C(=NO1)C(=O)N2CCN(CC2)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)[N+](=O)[O-] |
| Reference | </br>1: Bittker JA, Weiwer M, Lewis T, Shimada K, Yang WS, MacPherson L, Dandapani S, </br> Munoz B, Palmer M, Stockwell BR, Schreiber SL. Screen for RAS-Selective Lethal</br> Compounds and VDAC Ligands – Probe 2. 2011 Feb 10 [updated 2011 Dec 12]. Probe</br> Reports from the NIH Molecular Libraries Program [Internet]. Bethesda (MD):</br> National Center for Biotechnology Information (US); 2010-. Available from</br> http://www.ncbi.nlm.nih.gov/books/NBK98919/</br> PubMed PMID: 22834036.</br>2: Devarajan R, Ashraf M, Beck RO, Lemberger RJ, Taylor MC. Holmium: YAG</br> lasertripsy for ureteric calculi: an experience of 300 procedures. Br J Urol.</br> 1998 Sep;82(3):342-7. PubMed PMID: 9772868.</br>3: Weïwer M, Bittker JA, Lewis TA, Shimada K, Yang WS, MacPherson L, Dandapani S,</br> Palmer M, Stockwell BR, Schreiber SL, Munoz B. Development of small-molecule</br> probes that selectively kill cells induced to express mutant RAS. Bioorg Med Chem</br> Lett. 2012 Feb 15;22(4):1822-6. doi: 10.1016/j.bmcl.2011.09.047. Epub 2011 Sep</br> 28. PubMed PMID: 22297109; PubMed Central PMCID: PMC3528973.</br> </br> |
